2018 to 2024 saw rise in insurance denials for brand-name drugs. Insurance denials of initial attempts to fill brand-name prescription drugs with no generic competitors increased by more than two-thirds from 2018 to 2024, according to a study published online in the Journal of the American Medical Association.
A apuração publicada por medicalxpress.com vira base para uma leitura editorial direta e contextualizada.
Trechos de apoio da pauta: Insurance denials of initial attempts to fill brand-name prescription drugs with no generic competitors increased by more than two-thirds from 2018 to 2024, according to a study published online in the Journal of the American Medical Association.
- Ponto de atenção: 2018.
- Ponto de atenção: 2024.
- Ponto de atenção: rise.
Em resumo, a leitura editorial acompanha o impacto do tema no nicho Fitness.
